Skip to the page

Data / Drug companies / Amgen, Inc

Amgen, Inc: 95 products in the FDA NDC directory, labeler code 55513

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Amgen, Inc (labeler code 55513) lists 95 products in the FDA National Drug Code Directory, covering 25 finished drugs by generic name. By type: 87 prescription drugs, 8 drugs for further processing. Its main marketing category is biologics (BLA). The newest product started marketing on March 31, 2026.

The request: Watch Amgen, Inc (FDA labeler code 55513): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
55513
Products in commercial distribution
95
Packages
143
Finished drugs by generic name
25
Prescription products
87
Over the counter products
0
Flagged as original packager
78 of 78 products that carry the flag
Started marketing in the last 12 months
2
Products with a marketing end date set
3
Earliest marketing start
June 1, 1989
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Biologics (BLA)6770.5%
New drug applications (NDA)2021.1%
Drugs for further processing88.4%

Products by type

TypeProductsShare
Prescription drugs8791.6%
Drugs for further processing88.4%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Darbepoetin alfa141
Adalimumab-atto93
Apremilast81
Epoetin alfa61
Filgrastim42
Erenumab-aooe41
Pegfilgrastim32
Romosozumab-aqqg31
Sotorasib31
Cinacalcet hydrochloride31
Ivabradine312
Romiplostim31
Etelcalcetide31
Talimogene laherparepvec21
Rituximab-arrx21
Trastuzumab-anns21
Denosumab25
Tarlatamab-dlle21
Bevacizumab-awwb21
Panitumumab21
Aflibercept-ayyh21
Tezepelumab-ekko21
Eculizumab-aeeb11
Infliximab-axxq11
Blinatumomab11

Dosage forms

Dosage formProductsShare
Injection, solution2930.5%
Solution2324.2%
Injection1414.7%
Kit99.5%
Injection, powder, lyophilized, for solution66.3%
Tablet, coated66.3%
Tablet, film coated55.3%
Injection, suspension22.1%
Injection, solution, concentrate11.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Neulasta55513-099SolutionBiologics (BLA)March 31, 2026
Evenity55513-509Injection, solutionBiologics (BLA)January 1, 2026
Otezla55513-519Tablet, film coatedNew drug applications (NDA)August 29, 2025
Otezla55513-516KitNew drug applications (NDA)August 29, 2025
Bkemv55513-180Injection, solution, concentrateBiologics (BLA)March 1, 2025
Pavblu55513-065Injection, solutionBiologics (BLA)October 28, 2024
Pavblu55513-056Injection, solutionBiologics (BLA)October 28, 2024
Evenity55513-998Injection, solutionBiologics (BLA)July 1, 2024
Lumakras55513-512Tablet, coatedNew drug applications (NDA)June 27, 2024
Imdelltra (amg757)55513-077KitBiologics (BLA)May 16, 2024
Imdelltra (amg757)55513-059KitBiologics (BLA)May 16, 2024
Otezla55513-996KitNew drug applications (NDA)April 25, 2024
Otezla55513-508KitNew drug applications (NDA)April 25, 2024
Otezla55513-497Tablet, film coatedNew drug applications (NDA)April 25, 2024
Amjevita55513-482InjectionBiologics (BLA)August 14, 2023
Amjevita55513-481InjectionBiologics (BLA)August 14, 2023
Amjevita55513-480InjectionBiologics (BLA)August 14, 2023
Amjevita55513-479InjectionBiologics (BLA)August 14, 2023
Amjevita55513-399InjectionBiologics (BLA)August 14, 2023
Amjevita55513-413InjectionBiologics (BLA)April 6, 2023
Lumakras55513-504Tablet, coatedNew drug applications (NDA)February 2, 2023
Amjevita55513-411InjectionBiologics (BLA)January 31, 2023
Amjevita55513-410InjectionBiologics (BLA)January 31, 2023
Amjevita55513-400InjectionBiologics (BLA)January 31, 2023
Tezspire55513-123Injection, solutionBiologics (BLA)December 17, 2021

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.